-
Synonyms
Urokinase, PLAU, ATF, UPA, URK, u-PA，BDPLT5，QPD
-
Alternative_names
Urokinase, PLAU, ATF, UPA, URK, u-PA，BDPLT5，QPD
-
Description
A potent marker of invasion and metastasis in a variety of human cancers
-
Recombinant
Yes
-
Source
HEK 293 cells
-
Purity by SDS PAGE
≥92%
-
Assay
SDS-PAGE
-
Endotoxin Level
< 0.1 ng/ug of protein (
-
Activity Specifications test method
Measured by its ability to cleave a peptide substrate, N - carbobenzyloxy - Gly - Gly - Arg - 7 - amido - 4 - methylcoumarin (Z - GGR - AMC). The specific activity is > 2000 pmoles/min/ug.
-
Biological activity
Immobilized Human PLAU, His Tag at 5 ug/mL (100 ul/well) can bind Biotinylated Human uPAR, His, Avitag with a linear range of 0.3-2 ng/mL
-
Molecular Weight
This protein is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 45.0 kDa. The protein migrates as 45-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. Please note that the protein is not activated by protease digestion. In vitro activation is generally recommended for higher activity.
-
Storage Temp
-20°C
-
Shipping
Gel Pack
-
Shelf Life
12 months
-
Appearance
Lyophilized powder
-
Physical form description
Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).
-
Reconstitution Instructions
Centrifuge the vial prior to opening. Reconstitute in deionized water. Do not vortex. For extended storage, it is recommended to store at -70°C.
-
Background Information
Urokinase - type plasminogen activator also known as PLAU and UPA, a serine protease with extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium. The human PLAU is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues). The single chain molecule is processed into a disulfide-linked two-chain molecule of different molecular weights. Two forms of the A chain exist, starting at Ser21 (the long form) and Lys156 (the short form). The long and short A chains are unique to the high and low molecular weight forms, respectively. The long A chain contains an EGF-like domain, responsible for binding of the PLAU receptor. The B chain corresponds to the catalytic domain.
-
Handling
Centrifuge the vial prior to opening.
-
Usage
For Research Use Only! Not to be used in humans
-
-
Properties
Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.
-
Additional source
Recombinants or rec. proteins
-
Group
recombinants
